Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.66 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28686072 | 0.82 | BTK (0.82) | BTKFLT3TGFBR1HRH3ROCK2 | |
| SCHEMBL19202582 | 0.80 | BTK (1.00) | BTKFLT3HRH3ROCK2CDK2 | |
| SCHEMBL29129225 | 0.78 | BTK (0.56) | BTKTGFBR1HRH3JAK2CHEK1 | |
| SCHEMBL19203196 | 0.78 | BTK (0.74) | BTKFLT3JAK2ROCK2CDK2 | |
| SCHEMBL19202654 | 0.75 | BTK (0.59) | BTKCHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL24083375 | 0.75 | BTK (0.57) | BTKTGFBR1ROCK2AKT1AKT2 | |
| SCHEMBL19203183 | 0.69 | BTK (0.56) | BTK | |
| SCHEMBL19409822 | 0.67 | HRH3 (0.59) | TGFBR1HRH3JAK2CHEK1CDK7 | |
| SCHEMBL11930851 | 0.66 | CHEK1 (0.70) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL1936159 | 0.64 | CXCR4 (0.57) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602818-B | Pyrazole fused ring derivatives, preparation method thereof and application thereof in treating cancer, inflammation and immune diseases | 北京诺诚健华医药科技有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3409672-B1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-07-02 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| EP-3409672-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2018-12-05 | — | — | EP | disclosed |
| WO-2017128917-A1 | PARAZOLE CONDENSED-RING DERIVATIVES AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 北京诺诚健华医药科技有限公司 | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336755-B2 | Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases | BTK, SYK, JAK1 | BTK 1/4885KDM1A 1604/4885FLT3 13/4885 |
| US-20190016721-A1 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | BTK, SYK, JAK1 | BTK 1/4885KDM1A 1604/4885FLT3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.